NCT04117113View on ClinicalTrials.gov

Study to Collect Information About Invasive Disease Caused by Extraintestinal Pathogenic Escherichia Coli-2 (EXPECT-2)

CompletedOBSERVATIONAL
Enrollment

238

Participants

Timeline

Start Date

October 22, 2019

Primary Completion Date

January 31, 2021

Study Completion Date

May 12, 2021

Conditions
E. Coli Infection
Trial Locations (8)

27701

Duke Clinical Research Institute, Durham

41013

Andalusian Public Foundation for Health Research Management in Seville (FISEVI), Seville

50937

UKK Uniclinic Cologne, Cologne

87042

CHU Limoges - CIC, Limoges

Unknown

Duke Clinical Research Institute, Greater Sudbury

University of Verona, Verona

Janssen Pharmaceutical K.K., Tokyo

OX1 2JD

University of Oxford, Oxford

All Listed Sponsors
collaborator

Janssen Research & Development, LLC

INDUSTRY

collaborator

Innovative Medicines Initiative

OTHER

lead

UMC Utrecht

OTHER

NCT04117113 - Study to Collect Information About Invasive Disease Caused by Extraintestinal Pathogenic Escherichia Coli-2 (EXPECT-2) | Biotech Hunter | Biotech Hunter